Opening soon. Stay in the loop

goodmorrowJoin the opening list

Sermorelin, explained.

Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

More than one catalog form

The routine

Research has used scheduled injections, but the appropriate frequency, monitoring and tablet absorption need review for the exact formulation.

The evidence

Small human studies · wellness outcomes uncertain

Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.

Legal status
Compoundable now

Compoundable today with a prescription. It was an FDA-approved drug, Geref, until its maker stopped selling it in 2008 for business reasons.

At Goodmorrow
Offered when we open

What it is

Sermorelin is the first 29 amino acids of growth hormone releasing hormone, the signal your brain uses to tell the pituitary to release growth hormone. It was sold as an FDA-approved drug called Geref until 2008, when the manufacturer discontinued it for commercial reasons.

What the evidence shows

Sermorelin reliably raises growth hormone and IGF-1 in people with a working pituitary. Evidence that it improves body composition, sleep or recovery in healthy adults is limited to small studies and clinical experience.

How Goodmorrow handles it

We check IGF-1 before and during treatment, so your dose is set by your numbers rather than a template. It's usually a small injection at night.

Before you take it

  • Not for anyone with active cancer or who is pregnant. Common side effects are injection-site redness, flushing and headache.

Questions people ask

Is sermorelin the same as HGH?

No. HGH is growth hormone itself. Sermorelin asks your own pituitary to make more, which keeps your body's normal feedback in place.

Sermorelin or CJC-1295 and ipamorelin?

They work on the same pathway. The difference that matters today is that sermorelin is lawful to compound and the other two aren't.

Sources

  1. Secondary sourceThe US Peptide Status Index Peptide America
  2. Secondary sourceThe Peptide Reclassification Everyone's Talking About: A Pharmacist's Take Pharmacy Times, 2026

Good days ahead.

Join the opening list for appointment updates.

Join the opening list